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METHODS FOR DETECTING AND 
QUANTIFYING VIABLE BACTERIAL 
ENDO-SPORES 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
This application is related and claims priority to U.S. Pro-
visional Application entitled "Rapid fluorescent detection of 
viable bacterial endospores" Ser. No. 61/351,238, filed on 
Jun. 3, 2010 herein incorporated by reference in its entirety. 
This application is also related and claims priority to U.S. 
Provisional Application entitled "PMA-Phylochip, a DNA 
microarray to elucidate viable microbial community struc-
ture", Ser. No. 61/441,820, filed on Feb. 11, 2011, herein also 
incorporated by reference in its entirety. 
STATEMENT OF GOVERNMENT GRANT 
The invention described herein was made in the perfor-
mance of work under a NASA contract, and is subject to the 
provisions of Public Law 96-517 (35 USC 202) in which the 
Contractor has elected to retain title. 
FIELD 
The present disclosure relates to endospores. In particular 
the present disclosure related to methods and systems to 
detect viable bacterial endospore. 
BACKGROUND 
Bacterial endospores can survive without nutrients. They 
are resistant to ultraviolet radiation, desiccation, high tem-
perature, extreme freezing and chemical disinfectants. Com-
mon anti-bacterial agents that work by destroying vegetative 
cell walls don't work on endospores. Endospores are com-
monly found in soil and water, where they may survive for 
long periods of time. 
Development of a rapid and/or sensitive method for detect-
ing and in particular quantitatively detecting bacterial 
endospores has been challenging. 
SUMMARY 
Provided herein, are methods and systems for detecting 
viable bacterial endospores in a sample, which in several 
embodiments allow quantification of the detected viable 
endospores. Methods and systems herein described are based 
on detection of a first form of nucleic acid which is not 
comprised within the viable bacterial endospore, performed 
in connection with detection of a second form of nucleic acid 
which is comprised within the viable bacterial endospores 
According to a first aspect, a method and system for detect-
ing viable bacterial endospores in a sample is described. The 
method comprises contacting the sample with an agent, the 
agent being able to label the first form of nucleic acid to 
produce a first signal. The method further comprises detect-
ing the first signal from the sample, and treating the sample 
under a suitable condition to convert the second form of 
nucleic acid into the first form of nucleic acid, to produce a 
treated sample. The method further comprises contacting the 
treated sample with the agent able to label the first form of 
nucleic acid to produce a second signal, and detecting a 
second signal from the sample. The method also comprises 
subtracting the first signal from the second signal to detect 
viable endospores in the sample. 
According to a second aspect, a method and system of 
detecting viable bacterial endospores in a sample is 
described. The method comprises contacting the sample with 
an agent, the agent being able to label the first form of nucleic 
5 acid in the sample and interfere with amplification of the 
labeled first form of nucleic acid. The method further com-
prises treating the sample to produce an extract, the treating 
performed for a time and under condition to allow extraction 
from the sample of a nucleic acid comprising the first form of 
io nucleic acid and the second form of nucleic acid, and per-
forming nucleic acid amplification of the extract. The method 
further comprises detecting the amplification of extracted 
nucleic acid and detecting viable endospores in the sample 
based on the detected amplification product. 
15 	 According to a third aspect, a method and system for quan- 
titatively detect viable bacterial endospores in a sample is 
described. The method comprises contacting the sample with 
an agent able to label the first form of nucleic acid to produce 
a first signal. The method further comprises detecting the first 
20 signal from the sample following the contacting, and treating 
the sample under a suitable condition to convert the second 
form of nucleic acid into the first form of nucleic acid, to 
produce a treated sample. The method also comprises con-
tacting the treated sample with the agent able to label the first 
25 form of nucleic acid to produce a second signal and detecting 
the second signal from the sample. The method further com-
prises subtracting the first signal from the second signal, 
comparing the subtracted signal to a look-up table, the look-
up table comprising pre-determined signals associated to a 
3o quantity of the viable bacterial endospore, and determining 
the quantity of viable bacterial endospores in the sample. 
According to a fourth aspect, a method and system for 
quantitatively detecting viable bacterial endospores in a 
sample is described. The method comprises contacting the 
35 sample with an agent, able to label the first form of nucleic 
acid in the sample and interfere with amplification of the 
labeled first form of nucleic acid. The method further com-
prises treating the sample to provide an extract, the treating 
performed for a time and under conditions allowing extrac- 
40 tion of the first form of nucleic acid and the second form of 
nucleic acid from the sample, and amplifying the extracted 
nucleic acid. The method further comprises detecting a quan-
tity of the amplification of extracted nucleic acid following 
nucleic acid amplification, comparing the detected quantity 
45 of the amplification to a look-up table, which comprises pre-
determined quantities of amplification associated to quanti-
ties of viable bacterial endospores, and determining a quan-
tity of viable bacterial endospores in the sample. 
The methods herein described allow in several embodi- 
50 ments rapid and sensitive detection and quantification of 
viable endospores from a sample containing a mixture of 
entities, including but not limited to, viable and/or dead bac-
terial cells and/or endospores. The methods herein described 
also allow in several embodiments detection and quantifica- 
55 tion of viable bacterial endospores from samples of both low 
and high biomass. In particular, the methods herein described 
allow in several embodiments detection and quantification of 
viable bacterial endospores from a sample containing as few 
as 10 endospores, or from samples containing 10'-10 $ spores/ 
60 ml. 
The methods and systems herein described can be used in 
connection with applications wherein detection of viable 
endospore is desired, including but not limited to medical 
application, biological analysis and diagnostics including but 
65 not limited to clinical applications, food industry applications 
(e.g. validating food processing technologies, and/or sterility 
and quality of food), pharmaceutical and medical equipment 
US 9,228,240 B2 
3 
industries applications, (e.g. directed to spores detection as a 
marker for sterility), biosensors for bacterial detection in 
medical clinics, and microbial detection systems employed 
by governmental agencies, (e.g. directed to validating steril-
ization processes of USPS postal products, equipment and 
facilities, water treatment systems, and various public health 
applications). 
The details of one or more embodiments of the disclosure 
are set forth in the accompanying drawings and the descrip-
tion below. Other features, objects, and advantages will be 
apparent from the description and drawings, and from the 
claims 
BRIEF DESCRIPTION OF THE DRAWINGS 
The accompanying drawings, which are incorporated into 
and constitute a part of this specification, illustrate one or 
more embodiments of the present disclosure and, together 
with the detailed description and examples sections, serve to 
explain the principles and implementations of the disclosure. 
FIG. 1 shows a schematic representation of exemplary 
embodiments of the methods and systems herein described. A 
first exemplary method 1 is identified by the schematic illus-
tration of steps 1A-1B-1C-1D -1E and is possibly 
inclusive of the optional step 10. A second exemplary method 
2 is identified by the schematic illustration of steps 
2A-2B-2C and is possibly inclusive of the optional step 
20. 
FIG. 2 shows a reaction scheme illustration an exemplary 
nucleic acid modification performed by an exemplary agent 
suitable in methods and systems herein described. 
FIG. 3 shows a diagram reporting results of an exemplary 
amplification reaction using purified genomic DNA from E. 
coli before and after treatment with an exemplary agent 
herein described. 
FIG. 4 shows a diagram reporting results of an exemplary 
amplification performed for 16s ribosomal RNA gene using 
DNA-intercalating agent propidium monoazide (PMA). 
FIG. 5 shows a diagram reporting results of an exemplary 
amplification performed to quantify Bacillus pumilus 
endospores. 
FIG. 6 shows a diagram reporting results of an exemplary 
heat inactivation of Bacillus pumilus endospores at 90° C. 
The D-values for plate count and gPCR are 5 and 33 min, 
respectively. Curves are based on the averages of all results in 
triplicate. 
FIG. 7 shows a diagram reporting results of an exemplary 
UV inactivation of Bacillus pumilus endospores. Curves are 
based on the averages of all results in triplicate. 
DETAILED DESCRIPTION 
Provided herein, are methods for detecting and possibly 
quantifying viable bacterial endospores in a sample. 
The terms "detect" or "detection" as used herein indicates 
the determination of the existence, presence or fact of a target 
in a limited portion of space, including but not limited to a 
sample, a reaction mixture, a molecular complex and a sub-
strate. The "detect" or "detection" as used herein can com-
prise determination of chemical and/or biological properties 
of the target, including but not limited to ability to interact, 
and in particular bind, other compounds, ability to activate 
another compound and additional properties identifiable by a 
skilled person upon reading of the present disclosure. The 
detection can be quantitative or qualitative. A detection is 
"quantitative" when it refers, relates to, or involves the mea-
surement of quantity or amount of the target or signal (also 
4 
referred as `quantitation' ), which includes but is not limited to 
any analysis designed to determine the amounts or propor-
tions of the target or signal. A detection is "qualitative" when 
it refers, relates to, or involves identification of a quality or 
5 kind of the target or signal in terms of relative abundance to 
another target or signal, which is not quantified. 
The term "bacteria" as used herein refers to single-cell 
prokaryotic microorganism species typically of a few 
micrometers in length and a wide range of shapes, including 
io but not limited to Gram-negative bacteria and Gram-positive 
bacteria. The term "Gram-negative bacteria" refers to bacte-
rial species that do not retain crystal violet dye in the Gram 
staining protocol. In contrast, the wording "Gram-positive 
bacteria" refers to bacterial species that are stained dark blue 
15 or violet by Gram staining. Several Gram-positive bacteria 
form endospores, including but not limited to the genus Bacil-
lus and Clostridium. Bacillus bacteria are rod-shaped, aerobic 
or facultative, endospore-forming bacteria. The spores of 
Bacillus are particularly hard to lyse by either physical or 
20 chemical means due to its structure and composition. A spore 
core is surrounded by the core wall, a cortex and a spore coat. 
The term "bacterial endospore" as uses herein indicates a 
dormant and temporarily non-reproductive structure pro-
duced by certain bacteria, the formation of which is usually 
25 triggered under an unfavorable condition for bacteria, such as 
a lack of nutrients. The endospore typically consists of the 
bacterium's DNA and part of its cytoplasm, surrounded by a 
very tough outer coating, known as the endospore coat. Gen-
erally, when the environment becomes more favorable, the 
30 endospore can germinate to the metabolically active state, 
known as the vegetative state. Examples of bacteria able to 
form endospores comprise bacteria of the genus Bacillus and 
Clostridium. 
The term "viable" as used herein with reference to bacteria 
35 and endospore indicates a bacteria or endospore having a 
metabolic rate compatible with life. Exemplary viable bacte-
ria comprise normal and intact bacterial cells and bacteria in 
a viable but nonculturable (VBNC) state, wherein the bacteria 
is in a state of very low metabolic activity and do not repro- 
4o duce, but has the ability to become culturable once resusci-
tated (e.g under a favorable growth condition). Exemplary 
viable endospores comprise endospores capable of germinat-
ing under appropriate condition and endospores that are in a 
VBNC state. Bacteria and endospores can enter the VBNC 
45 state as response to for examples, stress, due to adverse nutri- 
ent, temperature, osmotic, oxygen, and light conditions. 
The term "sample" as used herein indicates a limited quan-
tity of something that is indicative of a larger quantity of that 
something, including but not limited to solids and/or fluids 
50 from a biological environment, specimen, cultures, tissues, 
commercial recombinant proteins, synthetic compounds or 
portions thereof. Exemplary samples in the sense of the cur-
rent disclosure include an environment sample collected from 
water, soil, air or the outer space, samples collected from a 
55 surface of a facility, equipment or system, food or pharma-
ceutical preparation. 
In several embodiments, methods and systems are 
described that can be used for detecting viable bacterial 
endospores in a sample are described. In methods and sys- 
60 tems detection is performed based on detection of two forms 
of nucleic acids in the sample: a first form of nucleic acid 
which is not comprised in the viable endospores, and a second 
form of nucleic acid which is comprised within the viable 
endospores. The first form of nucleic acid comprises nucleic 
65 acid included in a structure other than a viable endo spore (e.g. 
non-viable endospore, dead bacterial cell) or present in the 
sample outside any cell and/or endospore structure (e.g. 
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unbound nucleic acid sequences in free solution). The second 
form of nucleic acid is formed instead by nucleic acid within 
the viable endospore. 
The term "nucleic acid" as used herein indicates a poly-
meric form of nucleotides of any length, either ribonucle-
otides or deoxyribonucleotides, that comprise purine and 
pyrimidine bases, or other natural, chemically or biochemi-
cally modified, non-natural, or derivatized nucleotide bases. 
Nucleic acids of the embodiments of the current disclosure 
include Deoxyribonucleic acid (DNA), ribonucleic acid 
(RNA), or DNA copies of RNA (complementary DNA or 
cDNA), which may be isolated from natural sources, recom-
binantly produced, or artificially synthesized. The nucleic 
acids may exist as single-stranded or double-stranded and any 
chemical modifications thereof, provided only that the modi-
fication does not interfere with amplification of selected 
nucleic acids. For example, the backbone of the nucleic acid 
can comprise sugars and phosphate groups or modified or 
substituted sugar or phosphate groups, and a nucleic acid may 
comprise modified nucleotides, such as methylated nucle-
otides and nucleotide analogs. 
The methods herein described allow, in several embodi-
ments, qualitative and/or quantitative detection of viable bac-
terial endospores in a sample through use of agents are 
capable of selective binding with respect to the two forms of 
nucleic acid herein described. 
The term "agent' as used herein indicates a molecule, such 
as a ligand, or a chemical reagent that is capable of interacting 
with a nucleic acid molecule, such as a DNA molecule. The 
term "ligand" as used herein indicates a molecule that is 
recognized by a particular receptor. Exemplary receptors for 
a ligand in the sense of the current disclosure include, but are 
not restricted to polynucleotides and nucleic acids. The term 
"reagent" as usedherein indicates a substance, a compound or 
a mixture that is added to a system in order to bring about a 
chemical reaction or to examine whether a reaction occurs. 
Exemplary types of interaction between the agent and nucleic 
acids include covalent binding, electrostatic binding and 
intercalating. 
The term "covalent binding" indicates a process of forma-
tion of a chemical bonding that is characterized by sharing of 
pairs of electrons between atoms, known as the covalent 
bond. Covalent bonding indicates a stable balance of attrac-
tive and repulsive forces between atoms when the atoms share 
their electrons, and includes many kinds of interaction, 
including a-bonding, 7t-bonding, metal to metal bonding, 
agostic interactions, and three-center two-electron bonds. 
The term "electrostatic binding" indicates association 
between two oppositely charged entities. 
The term "intercalating" as used herein indicates a process 
when a nucleic acid intercalating agent fit itself in between 
base pairs of a nucleic acid molecule. Structural and chemical 
properties that are characteristic of nucleic acid intercalating 
agents often comprise a proper molecular size, being cationic, 
polycyclic, aromatic, planar and hydrophobic for the follow-
ing proposed mechanism of nucleic acid intercalation to take 
place: In aqueous isotonic solution, a cationic intercalating 
agent is attracted electrostatically to the polyanionic nucleic 
acid molecules. The intercalating agent displaces a sodium 
and/or magnesium cation that surrounds the nucleic acid, 
forming a weak electrostatic bond with the outer surface of 
the nucleic acid. From this position, the intercalating agent 
can slide into the hydrophobic environment found between 
the base pairs and away from the hydrophilic outer environ-
ment surround the nucleic acid. The base pairs transiently 
form such openings for the entering of the intercalating agent 
due to energy absorbed during collision with the solvent 
6 
molecules. Exemplary nucleic acid intercalating agents 
include propidium monoazide (PMA), ethidium monoazide 
bromide (EMA), ethidium bromide, berberine, proflavine, 
daunomycin, doxorubicin, and thalidomide. 
5 	 During intercalation, the nucleic acid dynamically opens a 
space between its base pairs by unwinding. The degree of 
unwinding varies depending on the specific intercalating 
agent. The unwinding of the base pairs induces local struc-
tural changes to the strand, such as lengthening of the strand 
i0 
or twisting the base pairs. These structural modifications can 
lead to in vivo functional changes, such as inhibition of tran-
scription, replication and/or repairing of the intercalated 
nucleic acid. For this reason, nucleic acid intercalating agents 
are often carcinogenic and are suitable to be used as potent 
is mutagens. One example of such intercalating agents is 
ethidium bromide (EB), which is commonly used as a fluo-
rescent dye that stains nucleic acid in molecular biology 
laboratories and technology, such as agarose gel electro-
phoresis. The chemical structure of ethidium bromide is 
20 shown below. 
25 
30 	 H2N NH2 
Ethidium Bromide 
35 In embodiments of methods and systems herein described, 
the agent used is able to selectively bind the first form of 
nucleic acid in the sample. 
The wording "selective", "specific" "specifically" or 
"specificity" as used herein with reference to the binding of a 
40 first molecule to second molecule refers to the recognition, 
contact and formation of a stable complex between the first 
molecule and the second molecule, together with substan-
tially less to no recognition, contact and formation of a stable 
complex between each of the first molecule and the second 
45 molecule with other molecules that may be present. Exem-
plary specific bindings are antibody-antigen interaction, cel-
lular receptor-ligand interactions, polynucleotide hybridiza-
tion, enzyme substrate interactions etc. The term "specific" as 
used herein with reference to a molecular component of a 
50 complex, refers to the unique association of that component 
to the specific complex which the component is part of. The 
term "specific" as used herein with reference to a sequence of 
a polynucleotide refers to the unique association of the 
sequence with a single polynucleotide which is the comple- 
55 mentary sequence. By "stable complex" is meant a complex 
that is detectable and does not require any arbitrary level of 
stability, although greater stability is generally preferred. The 
term "selective" "specific" "specifically" or "specificity" as 
used herein with reference to a chemical or biological activity 
60 of a first molecule to second molecule of a certain bacteria or 
group of bacteria refers to the ability of the first molecule to 
direct the activity towards the second molecule, together with 
substantially less to no activity between the first molecule and 
molecules that may be present of organisms other than the 
65 bacteria or group of bacteria. 
Accordingly the agent used in methods and systems herein 
described is able to recognize, contact and form a stable 
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complex with the first form of nucleic acid, together with 
substantially less to no recognition, contact and formation of 
a stable complex with the second nucleic acid that may be 
present and substantially no labeling of the second form of 
nucleic acid. The term "substantially" as used herein indi-
cates an extent of that does not materially affect the parameter 
at issue. 
In an embodiment, the agents selectively penetrate com-
promisedbio-membrane, such as cell membrane of deadbac-
teria and spore-coat of dead endospores, but are substantially 
impermeable to intact bio-membrane of viable cells and 
endospores. Only after penetrating through bio-membrane of 
bacteria, the agent is able to get access to and label bacterial 
nucleic acids. 
A schematic illustration of exemplary embodiments of the 
methods and systems herein described is reported in FIG. 1. 
According to a first exemplary embodiment (FIG.1 step lA to 
lE), the method comprises labeling a sample with an agent 
(for example with PMA) (FIG. 1 step lA), detecting a first 
signal (FIG. 1 step 113), treating the sample to convert the 
second form of nucleic acid and labeling the sample (FIG. 1 
step 1C), detecting a second signal (FIG. 1 step 11)), and 
subtracting the detected signals to detect the viable 
endospores (FIG.1 step lE). According to a second embodi-
ment (FIG.1 Steps 2A to 2C), the method comprises labeling 
the sample (FIG.1 step 2A), extracting nucleic acid from the 
sample (FIG.1 step 213), and amplifying the extracted nucleic 
acid (for example, with gPCR). (FIG. 1 step 2C). In some 
embodiments, each of the above method can further com-
prises pre-treating the sample to inactivate, and in particular 
kill, viable bacterial cells in the sample, for example by heat-
ing at about 85° C. for about 15 minutes (FIG.1 Step 10 and 
step 20) before the labeling step (FIG. 1 step 1A/2A). Addi-
tional embodiments based on the exemplary illustration of 
FIG. 1 are identifiable by a skilled person. 
As illustrated in the exemplary schematics of FIG. 1, in 
some embodiments, the agent can be conjugated with a 
labeled molecule, such as a probe, which can produce a sig-
nal. In particular, methods herein described allow, in several 
embodiments, qualitative and/or quantitative detection of 
viable bacterial endospores in a sample through detection of 
signals from the sample produced by a label (see FIG.1 steps 
1A to 1E). 
The term "labeled molecule" or "probe" as used herein as 
component of a complex or molecule refer to a molecule 
capable of detection, including but not limited to radioactive 
isotopes, fluorophores, chemiluminescent dyes, chro-
mophores, enzymes, enzymes substrates, enzyme cofactors, 
enzyme inhibitors, dyes, metal ions, nanoparticles, metal 
sols, ligands (such as biotin, avidin, streptavidin or haptens) 
and the like that are identifiable by a skilled person. As a 
consequence, the wording "signal' or "labeling signal' as 
used herein indicates the signal emitted from the agent itself 
or the probe conjugated to the agent that allows detection of 
the agent and consequently the labeled target, including but 
not limited to radioactivity, fluorescence, chemilumines-
cence, production of a compound in outcome of an enzymatic 
reaction and the like that are identifiable by a skilled person. 
In particular detection of signals can be performed in sev-
eral embodiments of the methods and systems herein 
described, from a labeled first form of nucleic acid as herein 
described. 
In embodiments herein described the sample is contacted 
with an agent, able to label the first form of nucleic acid and 
producing a corresponding first signal. In some embodi-
ments, the same or a corresponding sample can then be 
treated under a suitable condition to convert the second form 
8 
of nucleic acid comprised in viable bacterial endospores into 
the first form of nucleic acid. The method further comprises 
contacting the treated sample with an agent able to selectively 
label the first form of nucleic acid to provide a second signal, 
5 detecting the second signal from the sample, subtracting the 
first signal from the second signal to detect the viable 
endospores in the sample. 
As further illustrated in the schematics of FIG. 1(see steps 
2A to 2C), in some embodiments, the agent comprises a 
io nucleic acid intercalating agent, able after intercalating into a 
nucleic acid molecule, to also covalently link to the molecule, 
thereby interferes with amplification of the molecule and in 
particular with PCR amplification. For example, PMA is a 
high affinity photo-reactive DNA binding dye, which is 
15 weakly fluorescent by itself but becomes more fluorescent 
after binding to nucleic acids. PMA preferentially binds 
dsDNA with high affinity. Upon photolysis, the photo-reac-
tive azido group of the molecule is converted to a highly 
reactive nitrene radical, which readily reacts with any hydro- 
20 carbon moiety at the binding site to form a stable covalent 
nitrogen-carbon bond, thus resulting in permanent DNA 
modification which prevents PCR amplification of the DNA 
molecule (see FIG. 2). The chemical structure of PMA is 
shown below. Another fluorescent intercalating agent that 
25 covalently binds to and interferes with PCR amplification of 
nucleic acids is ethidium monoazide bromide (EMA), the 
chemical structure of which is also shown below. A person 
skilled in the art may recognize other types agents, including 
nucleic acid intercalating agents, which may be used in the 
30 method herein disclosed. 
N3 
	 /~--NH2 
35 
CHzCH3 
C-1-2-2," —CH3 
1 
40 	 2C1- 	 CH2CH3 
Ethidium Monoazide Bromide (EMA) 
11 
45 	 III 
50 
55 	
Propidium Monoazide (PMA) 
Accordingly, the methods herein described also allow, in 
several embodiments, detection of viable bacterial 
60 endospores in a sample through amplification techniques 
such as real-time quantitative PCR (gPCR). 
The term "real-time PCR", "real-time quantitative PCR" or 
"gPCR" as used herein indicate a laboratory technique based 
on the polymerase chain reaction (PCR), which is used to 
65 amplify and simultaneously quantify a target DNA molecule. 
For one or more specific sequence in a DNA sample, real-time 
PCR enables both detection and quantification. The quantity 
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can be either an absolute number of copies of the amplified 
DNA molecules or a relative amount when normalized to the 
DNA template input or additional normalizing genes or DNA 
molecule. The real-time PCR procedure follows the general 
principle of polymerase chain reaction with a key feature that 
the amplified DNA is detected as the reaction progresses i.e. 
in real time. Two common methods for detection of products 
of DNA amplification in real-time PCR are detecting non-
specific fluorescent dyes that intercalate with any double-
stranded DNA and detecting sequence-specific DNA probes 
consisting of oligonucleotides that are labeled with a fluores-
cent reporter whichpermits detection only after hybridization 
of the probe with its complementary DNA target. Real-time 
PCR can be combined with reverse transcription to quantify 
RNA molecule present in a sample. 
In particular some embodiments, methods herein 
described comprise contacting the sample with an agent able 
to label the first form of nucleic acid in the sample and 
interfere with amplification of the labeled first form of nucleic 
acid. The method further comprises treating the sample fol-
lowing the contacting for a time and under condition suitable 
to extract nucleic acid from the sample and then performing 
amplification of the extract acid (e.g. using real-time quanti-
tative PCR). The method further comprises detecting the 
amplification product to detect viable endospores in the 
sample. 
In some embodiments, the agent can be a nucleic acid 
intercalating agent, such as PMA or EMA. 
As also illustrated in the exemplary schematic illustration 
of FIG. 1(see step 10/20), in some embodiments the method 
can comprise pre-treating the sample under a suitable condi-
tions which inactivate and in particular kill viable bacterial 
cells in the sample but minimizes effects on viable 
endospores. 
In particular, in some embodiments, the pretreating can be 
performed by heating the sample to about 85' C. for about 15 
minutes. Additional approaches, including for example use of 
UV or chemical agents that are suitable for the pre-treating 
are identifiable by a skilled person and could be used in the 
alternative or in combination with the heating or one with the 
other. 
In several embodiments, contacting a sample with an agent 
can be performed through mixing the sample with the agent, 
for example, in a solution. In other embodiments, the contact-
ing is performed through spraying the agent, for example in a 
fluid or powder form, onto a surface where the sample is 
located and distributed. 
The term "solution" as used herein comprises a single-
phase or multiple phase liquid system, also including colloids 
and suspensions. Exemplary solutions include homogeneous 
mixture composed of two or more substances, where typi-
cally a solute is dissolved in another substance, known as a 
solvent. Additionally exemplary solutions in the sense of the 
disclosure include non-homogeneous mixtures such as 
chemical mixture in which one substance is dispersed evenly 
throughout another (colloids) and heterogeneous fluid con-
taining solid particles that are sufficiently large for sedimen-
tation (suspensions). 
In some embodiments, detecting a signal can be performed 
through image acquisition. In other embodiments, detecting a 
signal is performed through microscopy or spectroscopy. 
In some embodiments, the detected signal can be quanti-
fied through measuring a signal intensity, for example, bright-
ness of a fluorescent image, which also allows comparison 
and subtraction of signals obtained by multiple rounds of 
detections. 
10 
In various embodiments of the methods herein described 
comprises treating a sample under a suitable condition to 
convert the second form of nucleic acid to the first form of 
nucleic acid. Exemplary treatments can compromise the 
5 integrity and in particular remove or disintegrate spore-coat 
of the viable endospores in the sample and at the same time 
maintains integrity of the nucleic acid comprised within the 
viable endospores, so as to facilitate penetration of the agents 
into the viable endospores and labeling the nucleic acid com- 
io prised therein. For example according to some embodiments, 
since autoclaving viable bacterial endospores, (e.g. exposure 
to 121' C. for 15 to 20 minutes) results in partial degradation 
of the endospore DNA (see e.g. Example 3), the treating is 
performed by heating the sample to a temperature lower than 
15 121° C. 
Particularly, in some embodiments, the treating can be 
performed by heating the sample to a temperature within the 
range of 90 to 100° C., preferably for a duration of between 5 
to 30 minutes. See Example 4. 
20 In some embodiments, the treating can be performed by 
ultraviolet (UV) radiation (see e.g. Example 5). The term 
"UV radiation" or "UV light' as used herein indicates elec-
tromagnetic radiation with a wavelength shorter than that of 
visible light, but longer than X-rays, in the range of 10 nm to 
25 400 mu, and energy from 3 eV to 124 eV. 
Accordingly, in some embodiments, the treating can be 
performed by exposing the sample to UV radiation. In par-
ticular, in some embodiments, the treating is performed by 
exposing the sample to 245 nm UV radiation of a dose, 
30 preferably between 0.2-3 K7/m 2 
In some embodiments, the treating can be performed by 
contacting viable bacterial endospores to urea, e.g. a urea-
containing buffer results in disintegration of spore-coat (See 
Example 6). 
35 	 Accordingly, in some embodiments, the treating can be 
performed by exposing the sample to a buffer comprising 
urea. In particular, in some embodiments, the buffer com-
prises about 8M urea. In some embodiments, the buffer fur-
ther comprises about 5 mM cyclohexylaminoethane sulfonic 
4o acid, about 50 mM dithioerythritol and about 0.8% sodium 
dodecyl sulfate. In some embodiments, the buffer further 
comprises about 5 mg lysozyme. In some embodiments, the 
buffer is adjusted to a pH of about 9.8. 
Additional procedures suitable for performing the treating 
45 according to the various embodiments of methods and sys-
tems herein described comprise various combination of heat-
ing, UV treatment and/or use of chemicals as will be under-
stood by a skilled person in view of the present disclosure. 
In some embodiments, the methods and systems herein 
5o described allow quantitative detection of viable bacterial 
endospores in a sample are described. The term "quantify" or 
"quantification" as used herein indicates processes relate to or 
involve the measurement of quantity or amount of the target 
or signal (also referred as quantitation), which includes but is 
55 not limited to any analysis designed to determine the amounts 
or proportions of the target or signal. 
The methods herein described allow, in several embodi- 
ments, quantifying viable bacterial endospores in the sample 
through detection of signals from the sample. The method 
60 comprises contacting the sample with an agent, the sample 
comprising a first form of nucleic acid and a second form of 
nucleic acid, the agent being able to label the first form of 
nucleic acid in the sample and produce a signal, wherein the 
second form of nucleic acid consists nucleic acid comprised 
65 in viable bacterial endospores in the sample. The method 
further comprises detecting a first signal from the sample, 
treating the sample under a suitable condition to convert the 
US 9,228,240 B2 
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second form of nucleic acid comprised in the viable bacteria 	 EXAMPLES 
endospores into the first form of nucleic acid, thus to produce 
a treated sample contacting the treated sample with the agent 	 The methods and systems herein disclosed are further illus- 
again and detecting a second signal from the sample. The 	 trated in the following examples, which are provided by way 
method further comprises subtracting the first signal from the 5 of illustration and are not intended to be limiting. 
second signal, comparing the subtracted signal to a look-up 	 In particular, the following examples illustrate exemplary 
table, the look-up table comprising pre-determined signal 	 embodiments of the methods and systems for qualitative and/ 
associated to numbers of viable bacterial endospores, and 	 or quantitative detecting viable bacterial endospores in a 
determining a number of viable bacterial endospores in the 	 sample. A person skilled in the art will appreciate the appli- 
sample. 	 10 cability and the necessary modifications to adapt the features 
The methods herein described allow, in several embodi- 	 described in detail in the present section, to additional solu- 
ments, quantifying viable bacterial endospores in the sample 	 tions, methods and systems according to embodiments of the 
through real-time gPCR. The method comprises contacting 	 present disclosure. 
the sample with an agent, the sample comprising a first form 	 The following materials and methods where used in the 
of nucleic acid and a second form of nucleic acid, the agent 15 experiments illustrated in this section 
being able to label the first form of nucleic acid in the sample 	 Quantitative Real-Time PCR (gPCR): 
and interfere with PCR amplification of the labeled first form 	 The current protocol that has been chosen for use with 
of nucleic acid, wherein the second form of nucleic acid 	 gPCR is a SYBR Green I dye format. Universal Primers 
consists nucleic acid comprised in viable bacterial 	 targeting the 16S rRNA (1369F: CGG TGA ATA CGT TCY 
endospores in the sample. The method further comprises 20 CGG (SEQ ID NO: I); 1492R: GGW TAC CTT GTT ACG 
extracting the first form of nucleic acid and the second form of 
	
ACT T (SEQ ID NO:2)) gene sequence will be used for all 
nucleic acid from the sample, and amplifying the extracted 	 organisms. One µL of purified DNA will be amplified with 
nucleic acid using real-time quantitative PCR. The method 
	
16S rRNA primers in a 25 µL hot-start PCR reaction mixtures 
further comprises detecting a quantity of the amplification of 
	
for: 
extracted nucleic acid, comparing the detected quantity to a 25 	 Stage 1: Hold 95° C. for 120 sec 
look-up table, which comprises pre-determined quantities of 
	
Stage 2: 3-Temp Cycle Repeat for 40 times 
amplification associated to numbers of viable bacterial 
	
95° C. for 15 sec 
endospores, and determining a number of viable bacterial 
	
55° C. for 60 sec with optics ON 
endospores in the sample. 	 72 C for 20 sec 
The look-up table herein described can be any form and 30 	 Stage 3: Melt Curve 60° C. to 95° C. at 0.2° C./sec with 
format of arrangement of pre-determined relationship and 
	
Optic Chl ONThe gPCR protocol has been adapted from 
correspondence between two or more changing parameters. 	 Cooper, M., LaDuc, M. T., Probst, A., Vaishampayan, P., 
For example, a look-up table canbe in the format of a standard 
	
Stam, C., Benardini, J. N., Piceno,Y. M., Andersen, G. L., and 
curve, a table or a data base. Exemplary parameters that can 	 Venkateswaran, K. (2011) `Assessing the cleanliness of sur- 
be included in a look-up table according to the current dis- 35 faces: Innovative molecular approaches vs. standard spore 
closure includes pre-determined amount of nucleic acid with 	 assays." Appl Environ Microbiol, herein incorporated by ref- 
relation to an amount and/or number of bacterial endospores, 	 erence in its entirety. 
pre-determined intensity of signals detected from a sample 	 B. pumilus SAFR-032 gPCR. 
with relation to an amount and/or number of viable bacterial 
	
All quantitative PCR (gPCR) were carried out with a Cep- 
endospores in the sample, pre-determined copy number of 40 heid Smart Cycler system (Cepheid; Sunnyvale, Calif.). B. 
gPCR amplification of nucleic acid extracted from a sample 	 pumilus specific primers targeting a 380 base-pair region of 
with relation to an amount and/or number of viable bacterial 	 the DNA gyrase subunit B encoding gyrB gene were used for 
endospores in the sample. A skilled person would be able to 	 all amplifications. Reactions mixtures consisted of 2x Bio- 
identify other suitable parameters and ways of determining 	 rad iQ SYBR Green SuperMix (Bio-Rad Laboratories; Her- 
such parameters so to construct or modify a look-up table in 45 cules, Calif.), 10 mM each forward (5'-TGA AGA TGT GCG 
a suitable format upon reading the current disclosure. 	 AGA AGG CT-3') (SEQ ID NO:3) and reverse primers (5'- 
The agents and other reagents herein described can be 	 AGG ATC TTC CCT CTT AAC GG-3') (SEQ ID NO:4) and 
provided as a part of systems to perform any assay, including 	 nuclease free water to reach a final volume of 25 µL. Ampli- 
any of the assays described herein. The systems can be pro- 	 fication was achieved according to the following thermal 
vided in the form of kits of parts. In a kit of parts, the agents 50 cycling program: initial melting at 95' C. for 2 min. (1 cycle) 
and other reagents to perform the assay can be comprised in 	 followed by 40 cycles of melting at 95° C. for 15 sec, anneal- 
the kit independently. The agents and other reagents can be 	 ing of primers at 58° C. for 30 sec, and elongation at 72° C. for 
included in one or more compositions, and each agent and 
	
30 seconds. The limit of detection of this assay was deter- 
reagent can be in a composition together with a suitable 	 mined via standards whose threshold cycle (C T) values were 
vehicle. 	 55 obtained from serially diluted DNA originally extracted from 
Additional components can include labels reference stan- 	 a spore crop at 10 $ spores/mL. All subsequent serial dilutions 
dards, and additional components identifiable by a skilled 	 were verified via plate count enumerations on TSA. Determi- 
person upon reading of the present disclosure. In particular, 	 nation and selection of the threshold cycle (C z,) values has 
the components of the kit can be provided, with suitable 	 been adapted from Suzuki, M. T., Taylor, L. T., and DeLong, 
instructions and other necessary reagents, in order to perform 60 E. F. (2000) "Quantitative analysis of small-subunit rRNA 
the methods here described. The kit will normally contain the 	 genes in mixed microbial populations via 5'-nuclease 
compositions in separate containers. Instructions, for 	 assays". App. Environ. Microbiol., 66, 4605-4614, herein 
example written or audio instructions, on paper or electronic 	 incorporated by reference in its entirety. 
support such as tapes or CD-ROMs, for carrying out the assay, 	 Spore Production and Enumeration. 
will usually be included in the kit. The kit can also contain, 65 	 B. pumilus SAFR-032 cells were grown overnight in tryp- 
depending on the particular method used, other packaged 	 tic soy broth (TSB) at 32° C. The culture was transferred to 1 
reagents and materials (i.e. wash buffers and the like). 	 L of a nutrient deficient sporulation medium, and incubated at 
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32° C. with shaking at 200 rpm, for 4-5 days or until sporu-
lation is complete, as verified by phase contrast microscopy. 
Spores were harvested by repeated centrifugation and wash-
ing in buffer solutions at 4° C. Following washing and a final 
resuspension in ultrapure water, spores were heat shocked at 
80° C. for 15 min, immediately cooled in an ice bath and then 
stored at 4° C. Enumeration was performed by pour plating 
with tryptic soy agar (TSA) followed by incubation at 32° C. 
for 48 hours. Propidium monoazide (PMA) treatment. PMA 
treatment of bacterial endospores with the DNA intercalating 
agent PMA was performed after spore coat is disturbed but 
before the lysozyme treatment. In particular, PMA was added 
at a 12.5 µg/mL concentration followed by incubation in the 
dark. Thereafter, spores are exposed to a 500-W halogen light 
for 5 minutes to intercalate PMA to the DNA. Following 
PMA treatment, spores are pelleted and suspended in PBS 
with sucrose. Lysozyme is added followed by incubation at 
37° C. for 60 min. Spores are again pelleted and subjected to 
DNA isolation. More details of the PMA treatment of bacte-
rial endospores can be found in Helen Rawsthome et al., 
"PCR-based method using propidium monoazide to distin-
guish viable from nonviable Bacillus subtilis spores," Applied 
and Environmental Microbiology 75 (2009): pp. 2936-39, 
herein incorporated by reference in its entirety. 
Isolation of Bacterial Endospores. 
The procedure for isolating bacterial endospores can be 
found in La Duc, M. T., Dekas, A. E., Osman, S., Moissl, C., 
Newcombe, D., and Venkateswaran, K. (2007) Isolation and 
characterization of bacteria capable of tolerating the extreme 
conditions of clean-room environments. Appl. Environ. 
Microbiol., 73, 2600-2611, herein incorporated by reference 
in its entirety. 
Bacterial DNA Preparation. 
Bacterial DNA was isolated using the Mo Bio Ultra-Clean 
Microbial DNA Isolation kit following manufacturer's 
instructions (Mo Bio Laboratories Inc.; Carlsbad, Calif.). 
More details of the procedure of extracting bacterial DNA 
from cells and endospores can be found in La Duc, M. T., 
Osman, S., and Venkateswaran, K. (2009) "Comparative 
analysis of methods for the purification of DNA from low-
biomass samples based on total yield and conserved micro-
bial diversity". J. Rapid Meth. Auto. Microbiol., 17,350-368, 
herein incorporated by reference in its entirety. 
PMA Fluorescence Measurement. 
After spore-coat removal or disintegration, the sample was 
treated with PMA as described above and subjected to fluo-
rescent microscopy analysis. Fluorescence at 610 nm was 
acquainted and measured with a Fluorolog-3 Fluorescence 
spectrometer (Horiba Tobin-Yvon) under 510 nm excitation. 
Example 1 
PMA Intercalates with DNA and Blocks PCR 
Amplification 
Genomic DNA isolated from E. coli was used as the model 
for the proof-of-concept that PMA can be used to intercalate 
DNA making it unavailable for PCR amplification. In par-
ticular, PMA was added at a 12.5 µg/mL concentration to the 
purified E. coli DNA sample followed by incubation in the 
dark. Thereafter, the sample was exposed to a 500-W halogen 
light for 5 minutes to intercalate PMA to the DNA. 
As shown in FIG. 3, isolated DNA without PMA treatment 
can be amplified within 26 cycles. In contrast, isolated DNA 
with PMA treatment was not amplified after 40 cycles (nega-
tive). 
14 
Example 2 
Real-Time PCR Amplification Using DNA Extracted 
from Bacterial Endospores 
5 
Bacterial endospores of Bacillus pumilus are exposed to 
various treatments, before the endospore DNA was extracted 
and tested with real-time PCR. Specifically, the amplification 
target is the 16S ribosomal RNA gene. A negative control of 
10 
no DNA template was included. 
First, the effect of heat treatment on PCR amplification of 
endospore DNA was examined. In particular, DNA was 
extracted from SAFR-032 spores that are viable (SAFR-032 
15 control) and after autoclaving for 15 min at 121' C. (SAFR-
032 Autoclaved). As seen in the results shown in FIG. 4, DNA 
was not amplifiable after autoclaving, which is possibly due 
to a degradation of DNA, especially at the primer regions, 
during the autoclaving. Therefore, it is desired to expose 
20 endospores to a milder treatment, which is suitable to kill the 
viable endospores and leave endospore DNA intact and 
amplifiable using PCR. 
Next, whether PMA can intercalate with Bacillus pumilus 
DNA was examined. In particular, DNA was extracted from 
25 Bacilluspumilus vegetative cells (DNA control), an aliquot of 
which was treated with PMA (DNA treated with PMA). As 
shown in FIG. 4, the control DNA was amplified with 26 
cycles, and the PMA treated DNA was not amplified after 40 
cycles (negative). This is consistent with the results shown in 
30 FIG. 3, which suggest that PMA intercalates with and blocks 
PCR amplification of DNA extracted from E. coli and Bacil-
lus pumilus cells in a similar manner. 
Additionally, the effect of endospore coat on PCR ampli-
fication of endospore DNA was examined. In particular, live 
35 endospores of Bacillus pumilus were purified and cleaned 
with two chemical agents, isopropyl alcohol (I, Live 
Destained 1 (1)) and acetone (A, Live Destained 2 (A)), which 
have been shown to be able to destain and remove PMA from 
PMA-stained endospore coat. PMA treated live endospores 
40 were then treated with the two chemicals for 24 hours, respec-
tively. Following the chemical treatment, endospore DNA 
was extracted and tested with real-time PCR. As shown in 
FIG. 4, cleaning endospore coat with the two chemicals does 
not produce a significant impact on real-time PCR amplifica- 
45 tion. A threshold of amplified copy number was reached 
within 30 cycles with isopropyl alcohol treatment and within 
32 cycles with acetone treatment. Note that, the threshold was 
reached within 29 cycles for endospore DNA without chemi-
cal treatment (SAFR-032 control). 
50 
Example 3 
Identification of Suitable Conditions of Treatment of 
Bacterial Endospores for PMA or PMA-gPCR Based 
55 	 Detection and Quantification of Viable Endospores 
A set of experiments was performed to identify the suitable 
treatment conditions of bacterial endospores for PMA or 
PMA-gPCR based detection and quantification of viable 
60 endospores. In particular, viable endospores of Bacillus 
pumilus are exposed to various treatments, before the 
endospore DNA was extracted and tested with real-time PCR. 
Specifically, the amplification target is the gyrB gene. 
In order to detect and quantify viable endospores using the 
65 PMA or PMA-gPCR method, PMA need to penetrate through 
the endospore coat and to intercalate and blocking PCR 
amplifications of the endospore DNA. 
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A first experiment was performed to examine whether 
PMA can penetrate through viable endospore coat of Bacillus 
pumilus. In particular, endospore DNA was extracted from 
viable endospores before (viable spores) and after (PMA 
viable spores) the endospores were treated with PMA. As 5 
shown in FIG. 5, no significant effect of PMA on PCR ampli-
fication was observed. Specifically, a threshold of amplified 
copy number was reached within 15 and 16 cycles respec-
tively. These results indicate that viable endospores block 
PMA 10 
Therefore, it is desired to treat the viable endospores under 
a suitable condition, so that the endospore coat is disturbed 
and becomes preamble to PMA while endospore DNA is 
intact and remains amplifiable for PCR. To identify such 15 
treatment condition, the following experiments were per-
formed. 
Heat Treatment. 
Using the method of Rawsthorne et al (2009), herein 
enclosed by reference in its entirety, viable Bacillus pumilus 20 
SAFR-032 endospores were heat treated at 121' C. for 15 min 
(15 min autoclaved spores) or 30 min (twice autoclaved 
spores). After the heat treatment, an aliquot of each of the 
treated samples was further treated with PMA (PMA 15 min 
autoclaved spores, PMA twice autoclaved spores). Then, 25 
endospore DNA was extracted from the samples and tested 
with real-time PCR. As shown in FIG. 5, gPCR of the PMA 
treated samples consistently undergo more cycles to reach a 
threshold of amplified copy number, which reflects partial 
blocking of PCR amplification by PMA. These results sug- 30 
gest that after the 15 min heat treatment at 121 1 C., PMA 
penetrate through the endospore coat and intercalate with 
endospore DNA. 
Notably, real-time PCR for the 15 min autoclaved spores 
and the twice autoclaved spores undergoes significantly more 35 
cycles to reach the threshold when compared to real-time 
PCR for the viable spores. This suggests that endospore DNA 
after 15 min or 30 min heat treatment at 121 1 C. is partially 
degraded, which is consistent with the results shown in FIG. 
5. Therefore, a milder heat treatment is preferred. 40 
Chemical Treatment. 
Viable Bacillus pumilus SAFR-032 endospores were 
chemically treated with a DTT based buffer (DTT viable 
spores). 
After the chemical treatment, an aliquot of the treated 45 
sample was further treated with PMA (DTT PMA viable 
spores). Then, endospore DNA was extracted from the 
samples and tested with real-time PCR. As shown in FIG. 5, 
chemical treatment of DTT based buffer does not effect on the 
real-time PCR amplification. Specifically, real-time PCR for 50 
DTT viable spores and DTT PMA viable spore both reach the 
threshold of amplified copy number within about 20 cycles. 
Combined Heat and Chemical Treatment. 
Further, the heat treatment is combined with the DTT-
based chemical treatment. In particular, viable Bacilluspumi- 55 
lus SAFR-032 endospores were first heat treated at 121° C. 
for 15 min or 30 min, followed by chemical treatment using 
the DTT-based buffer as described above (DTT 15 autoclaved 
spores, DTT twice autoclaved spores). After that, an aliquot 
from each of the treated sample was further treated with 60 
PMA. Then, endospore DNA was extracted from the samples 
and tested with real-time PCR. As shown in FIG. 5, real-time 
PCR for endospore samples after the combined heat and 
chemical treatment undergo significant more cycles to reach 
the threshold of amplified copy number. In particular, 65 
endospore DNA spores is amplified after more than 35 cycles 
for the DTT 15 min autoclaved sample, and is not amplified  
16 
for DTT PMA 15 min autoclaved spores, DTT twice auto-
claved spores and DTT PMA twice autoclaved spores within 
40 cycles (negative). 
These results suggest that the DTT-based chemical treat-
ment is not suitable for the PMA or PMA-gPCR based detec-
tion and quantification of viable bacterial endospores. 
Example 4 
Identification of Suitable Conditions for Heat 
Treatment of Bacterial Endospores for PMA or 
PMA-gPCR Based Detection and Quantification of 
Viable Endospores 
As discussed in Example 2 above, endospore DNA is par-
tially degraded during the heat treatment at 121' C., which 
may reduce sensitivity and/or accuracy of viable endospore 
detection and quantification using the subsequent PMA-
gPCR method. 
Therefore, a set of experiments was performed to identify 
milder conditions of the heat treatment that are suitable to 
disturbing the endospore coat, making it permeable to PMA, 
and at the same time keep endospore DNA intact and ampli-
fiable using PCR. 
In particular, sterile aluminum thermal death tubes were 
prepared by adding 1.0 mL of spore crop (undiluted spore 
suspensions at a concentration of approximately 10 $ -109 
spores/ml) and sealed. Capillary tubes were placed in an oil 
bath at various temperature intervals ranging from 90-121' C. 
The time intervals ranged from seconds to minutes at the 
various temperatures. Thermal death tubes were removed 
from the oil bath and placed immediately in an ice bath for 5 
min, and then sterilized by immersion in a 3% hypochlorite 
solution for 30 sec. The ends of the thermal death tube were 
removed and 5 ml of peptone was flushed through the tube to 
remove the spore sample followed by 10-fold serial dilution 
and plating for enumeration. 
As shown in FIG. 6, heat inactivation of Bacillus pumilus 
endospores at 90° C. (as measured by the plate count) exhibits 
a linear relationship with the time (FIG. 6, circle). This result 
indicates that the heat treatment at 90° C. is challenging the 
cultivability of the endospores because the endospores are 
either killed or forced to render into the "viable but non-
cultivable" (VBNC) state. 
Following the heat treatment, endospore samples were 
treated with PMA before endospore DNA was extracted and 
tested with real-time PCR. As shown in FIG. 6, substantial 
amount of the target gyrB gene was amplified using PCR 
(FIG. 6 triangle), which indicates that the target gyrB was not 
significantly degraded during the heat treatment at 90° C. 
Further, a decline of amplification was observed (FIG. 6 
triangle), which may reflect the intercalating effect of PMA 
on the endospore DNA. 
These results suggest that heat treating the endospores at a 
lower temperature of 90° C. for a duration of up to 35 minutes 
could be a suitable condition for treating bacterial endospores 
before the PMA-gPCR based detection and quantification of 
viable endospores. 
Example 5 
Identification of Suitable Conditions of UV 
Treatment of Bacterial Endospore for PMA or 
PMA-gPCR Based Detection and Quantification of 
Viable Endospores 
A set of experiments was performed to explore alternative 
treatment conditions of bacterial endospores suitable for the 
PMA or PMA-gPCR based method. 
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In the following experiment, viable endospore samples 
(Bacillus pumilus SAFR-032) were exposed to various dose 
of UV radiation at a wavelength of 254 mu. More details 
about the UV treatment can be found in Newcombe, et al. 
2005, "Survival of spacecraft-associated microorganisms 
under simulated martian UV irradiation." Appl. Environ 
Microbiol, Vol. 71, pp 8147-8156. 
As shown in FIG. 7, UV inactivation of viable endospores 
(as measured by the plate count) exhibits linear relationship 
with the UV254 dose (FIG. 7 circle). This result indicates that 
the UV treatment at 254 nm is challenging the cultivability of 
the endospores because the endospores are either killed or 
forced to render into the "viable but non-cultivable" (VBNC) 
state. 
Following the UV treatment, endospore samples were 
treated with PMA before endospore DNA was extracted and 
tested with real-time PCR. As shown in FIG. 7, substantial 
amount of the target gyrB gene was amplified using PCR 
(FIG. 7 triangle), which indicates that the target gyrB was not 
significantly degraded during the UV treatment. Further, a 
decline of amplification was also observed (FIG. 7 triangle), 
which may reflect the intercalating effect of PMA on the 
endospore DNA. 
These results suggest that exposing the endospores to 245 
mu UV radiation with a dose of between 0.2-3 K7/could be a 
suitable condition for treating bacterial endospores for the 
PMA or PMA-gPCR based detection and quantification of 
viable endospores. 
Example 6 
Identification of Suitable Conditions of Chemical 
Treatment of Bacterial Endospore for PMA or 
PMA-gPCR Based Detection and Quantification of 
Viable Endospores 
The following experiments were performed to identify 
suitable conditions of chemical treatment of bacterial 
endospores for the PMA or PMA-gPCR based detection and 
quantification of viable endospores. 
Spore-coat disintegration was performed by pelleting and 
suspending the B. pumilus spores in spore coat extraction 
buffer containing urea (5 mM cyclohexylaminoethane sul-
fonic acid, 8M urea, 50 mM dithioerythritol, 0.8% sodium 
dodecyl sulfate, PH 9.8) to remove the outer spore coats. 
Spores were incubated at 60° C. for I hour in, pelleted and 
suspended in PBS with 25% sucrose. To promote degradation 
of the cortex, 50 µL of a 100 mg/mL solution of lysozyme is 
added followed by incubation at 37° C. for 60 min. After 
lysozyme treatment, spores are further pelleted and subjected 
to PMA treatment or DNA extraction as described above. 
Example 7 
Detection and Quantification of Viable Bacterial 
Endospores Based on PMA-Fluorescence 
Measurement 
Detection and quantification of viable bacterial endospores 
were performed using techniques previously illustrated in 
this section. 
The examples set forth above are provided to give those of 
ordinary skill in the art a complete disclosure and description 
of how to make and use the embodiments of the arrange-
ments, devices, compositions, systems and methods of the 
disclosure, and are not intended to limit the scope of what the 
inventors regard as their disclosure. All patents and publica- 
tions mentioned in the specification are indicative of the lev-
els of skill of those skilled in the art to which the disclosure 
pertains. 
The entire disclosure of each document cited (including 
5 patents, patent applications, journal articles, abstracts, labo-
ratory manuals, books, or other disclosures) in the Back-
ground, Summary, Detailed Description, and Examples is 
hereby incorporated herein by reference. All references cited 
in this disclosure are incorporated by reference to the same 
io extent as if each reference had been incorporated by reference 
in its entirety individually. However, if any inconsistency 
arises between a cited reference and the present disclosure, 
the present disclosure takes precedence. Further, the paper 
copy of the sequence listing submitted herewith and the cor- 
15 responding computer readable form are both incorporated 
herein by reference in their entireties. 
The terms and expressions which have been employed 
herein are used as terms of description and not of limitation, 
and there is no intention in the use of such terms and expres- 
20 sions of excluding any equivalents of the features shown and 
described or portions thereof, but it is recognized that various 
modifications are possible within the scope of the disclosure 
claimed Thus, it should be understood that although the dis-
closure has been specifically disclosed by preferred embodi- 
25 ments, exemplary embodiments and optional features, modi-
fication and variation of the concepts herein disclosed can be 
resorted to by those skilled in the art, and that such modifi-
cations and variations are considered to be within the scope of 
this disclosure as defined by the appended claims. 
30 	 It is also to be understood that the terminology used herein 
is for the purpose of describing particular embodiments only, 
and is not intended to be limiting. As used in this specification 
and the appended claims, the singular forms "a," "an," and 
"the" include plural referents unless the content clearly dic- 
35 tates otherwise. The term "plurality" includes two or more 
referents unless the content clearly dictates otherwise. Unless 
defined otherwise, all technical and scientific terms used 
herein have the same meaning as commonly understood by 
one of ordinary skill in the art to which the disclosure pertains. 
40 When a Markush group or other grouping is used herein, all 
individual members of the group and all combinations and 
possible subcombinations of the group are intended to be 
individually included in the disclosure. Every combination of 
components or materials described or exemplified herein can 
45 be used to practice the disclosure, unless otherwise stated. 
One of ordinary skill in the art will appreciate that methods, 
device elements, and materials other than those specifically 
exemplified can be employed in the practice of the disclosure 
without resort to undue experimentation. All art-known func- 
50 tional equivalents, of any such methods, device elements, and 
materials are intended to be included in this disclosure. 
Whenever a range is given in the specification, for example, a 
temperature range, a frequency range, a time range, or a 
composition range, all intermediate ranges and all subranges, 
55 as well as, all individual values included in the ranges given 
are intended to be included in the disclosure. Any one or more 
individual members of a range or group disclosed herein can 
be excluded from a claim of this disclosure. The disclosure 
illustratively described herein suitably can be practiced in the 
6o absence of any element or elements, limitation or limitations 
which is not specifically disclosed herein. 
A number of embodiments of the disclosure have been 
described. The specific embodiments provided herein are 
examples of useful embodiments of the disclosure and it will 
65 be apparent to one skilled in the art that the disclosure can be 
carried out using a large number of variations of the devices, 
device components, methods steps set forth in the present 
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description. As will be obvious to one of skill in the art, 
methods and devices useful for the present methods can 
include a large number of optional composition and process-
ing elements and steps. 
In particular, it will be understood that various modifica- 5 
tions may be made without departing from the spirit and 
scope of the present disclosure. Accordingly, other embodi-
ments are within the scope of the following claims. 
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What is claimed is: 
1. A method to detect a viable bacteria cell and/or 
endospore in a sample, the method comprising: 
contacting the sample with an agent to produce a first 
signal, upon the labeling of a nucleic acid from the 
non-viable bacterial cell and/or endospore; 
after contacting the sample with the agent to produce the 
first signal, detecting the first signal from the sample; 
treating the sample to render accessible nucleic acids from 
the viable bacterial cell and/or endospore; 
after the treating, contacting the sample with the agent to 
produce a second signal, the second signal produced 
upon labeling of the nucleic acids rendered accessible 
from the viable bacterial cell and/or endospore; 
after contacting the sample with the agent to produce the 
second signal, detecting the second signal from the 
sample; and 
subtracting the first signal from the second signal to detect 
the viable bacteria cells and/or endospore in the sample. 
2. The method of claim 1, wherein the agent is selected 
from the group consisting of propidium monoazide (PMA), 
ethidium monoazide bromide (EMA), ethidium bromide, 
berberine, proflavine, daunomycin, doxorubicin, and thalido-
mide. 
3. The method of claim 1, further comprises: 
pretreating the sample for a time and under conditions 
suitable to kill viable bacterial cells or a portion thereof 
before contacting the sample with the nucleic acid inter-
calating agent. 
4. The method of claim 3, wherein the pretreating com-
prises heating the sample up to about 85° C. for about 15 
minutes. 
5. The method of claim 1, wherein the treating comprises 
heating the sample to a temperature within the range between 
about 90° C. and about 100° C. 
6. The method of claim 5, wherein the heating is performed 
for a duration from about 5 minutes to about 30 minutes. 
7. The method of claim 1, wherein the treating comprises 
exposing the sample to UV radiation. 
22 
8. The method of claim 7, wherein the UV radiation has a 
wavelength of about 245 mu. 
9. The method of claim 8, wherein the UV radiation is 
provided in a dose of from about 0.2 to about 3 K7/m 2 . 
5 	 10. The method of claim 1, wherein the treating comprises 
contacting the sample to urea. 
11. The method of claim 10, wherein the urea is at a buffer 
concentration of about 8M. 
12. The method of claim 11, wherein buffer comprises 
10 about 5 mM cyclohexylaminoethane sulfonic acid, about 50 
mM dithioerythritol, about 0.8% sodium dodecyl sulfate, and 
about 5 mg lysozyme. 
13. The method of claim 1, wherein the first signal and/or 
the second signal is a fluorescent signal. 
15 	 14. A method to detect a viable bacteria cell and/or 
endospore in a sample, the method comprising: 
labeling the sample with a nucleic acid intercalating agent 
capable of selectively binding to a nucleic acid from 
non-viable bacterial cells and/or endospores to produce 
20 	 a first signal; 
after labeling the sample with the nucleic acid intercalating 
agent to produce the first signal, detecting the first signal 
from the sample; 
treating the sample by heating the sample to a temperature 
25 for a suitable duration or by exposing the sample to 
ultraviolet (UV) radiation or by contacting the sample to 
one or more chemicals to render accessible nucleic acids 
from the viable bacterial cell and/or endospore; 
after the treating, labeling the sample with the nucleic acid 
30 intercalating agent to produce a second signal, the sec-
ond signal produced upon labeling of the nucleic acids 
rendered accessible from the viable bacterial cell and/or 
endospore; 
after labeling the sample with the nucleic acid intercalating 
35 	 agent to produce the second signal, detecting the second 
signal from the sample; and 
subtracting the first signal from the second signal to detect 
the viable bacteria cells and/or endospore in the sample. 
